The bladder exstrophy-epispadias complex (BEEC) comprises of a spectrum of anterior midline defects, all affecting the lower urinary tract, the external genitalia, and the bony pelvis.
| INTRODUCTION
The mammalian urinary bladder serves as a storage organ for urine made by the kidney, intermittently voiding its contents through the urethra. In humans, the bladder rudiment is evident at the sixth week of gestation, when the cloaca has become divided into the urogenital sinus and hindgut. Over the next 2 months, the bladder wall differentiates into detrusor smooth muscle, itself invaded by autonomic nerves, with the bladder lumen lined by a water-tight urothelium (Jenkins, Winyard, & Woolf, 2007) . The human bladder is subject to a range of malformations including: prune belly and megacystis-microcolon-intestinal hypoperistalsis syndromes, where the detrusor is acontractile; urofacial syndrome, where there is a functional bladder outflow obstruction; and vesicoureteric reflux, where urine moves retrogradely from bladder into the upper tract (Woolf, Stuart, & Newman, 2014) . Importantly, such diseases can manifest as monogenic diseases with the implicated genes coding for molecules affecting neural (Newman & Woolf, 1993 -2018 Weber et al., 2011) , smooth muscle (Thorson et al., 2014) , and epithelial (Jenkins et al., 2005) biology.
Human urinary tract malformations also feature in the bladder exstrophy-epispadias complex (BEEC) (MIM 600057) . The term BEEC describes a spectrum of midline anomalies of the anterior abdominal wall, bony pelvis, urinary tract, genitalia, hindgut, and spine (Purves & Gearhart, 2010) . The mildest form is epispadias, where the urethra opens on the anterior surface of the penis rather than on its top.
The next most severe form is classic bladder exstrophy (CBE) where the ventral part of the bladder is open, with urothelium exposed on the body surface. The most severe form is cloacal exstrophy (CE) where there is an imperforate anus and the gastro-intestinal tract is abnormal. This variant is also called the omphalocele, exstrophy, imperforate anus, and spinal defects (OEIS) complex. A European survey of pediatric urology centers revealed that they were caring for 238 babies that had been born with BEEC over a single year: 71 cases had epispadias, of which 92% were male; 146 had CBE, of which 66% were male; and 21 had CE, of which 81% were male (Cervellione et al., 2015) . A congenital anomaly survey of 824,368 fetuses, stillbirths, and live-born babies in Northern England calculated the prevalence for BEEC as 5.2 per 100,000 (Jayachandran, Bythell, Platt, & Rankin, 2011) . Among 26.3 million international births, CBE had an overall prevalence of 2.07 per 100,000, with a positive correlation with maternal age (Siffel et al., 2011) . A large international study calculated the prevalence of CE as 0.76 per 100,000 live births, with no relation to maternal age (Feldkamp et al., 2011) . Positive associations have been noted for CE with "use of any fertility medication or assisted reproductive technology" (Keppler-Noreuil et al., 2017) . Only 10% of BEEC cases are detected by routine antenatal ultrasonography (Jayachandran et al., 2011) .
Most individuals affected by BEEC have no associated congenital anomalies, and have no positive family history for BEEC. A twin study reported significantly higher concordance rates for BEEC in monozygotic (62%) compared with dizygotic (11%) twins (Reutter et al., 2007) , consistent with a strong genetic effect. Wilkins et al., 2012 , reported that an insertion/deletion polymorphism in the P63 promoter, which controls expression of an isoform ΔNp63, was a significant risk factor for BEEC.
A genome-wide association study in CBE identified a variant at 5q11.1-q11.2 close to ISL1 (ISL LIM homeobox 1; Zhang et al., 2017) . This association together with functional studies in mouse embryos and zebrafish larvae suggest ISL1 as a susceptibility gene for CBE and as a regulator of urinary tract development.
Further, a number of different chromosomal aberrations have been reported in individuals with BEEC. These include: a de novo unbalanced translocation between the long arms of chromosomes 9 and Y resulting in a 9q34.1-qter deletion (Thauvin-Robinet et al., 2004 ); a balanced translocation, 46,XY,t(8;9)(p11.2;q13), with the 9q13 breakpoint disrupting CNTNAP3 (Boyadjiev et al., 2005) ; and the deletion del(3)(q12.2q13.2) (Kosaki et al., 2005) . Microduplications involving 22q11.2 have been reported in a number of individuals with BEEC, including two out of 69 cases versus one of 171 controls (Lundin et al., 2010) ; out of 66 BEEC cases, one with a de novo microduplication of 22q11.21 and one where the duplication transmitted from the unaffected mother (Draaken et al., 2010); and 22q11.21 duplications in four of 244 BEEC cases and one of 665 controls. Considering these eight cases with 22q11.21 duplications (summarized in Table 1 of this article), it was calculated that this conferred an odds ratio of 31.86 (Draaken et al., 2014) .
The aim of this present study was to identify potentially pathogenic copy number variants (CNVs) in individuals with BEEC in a previously unstudied UK cohort. We report two unrelated cases with a 22q11.21 duplication out of 92 patients. In addition, we report a distal 22q11.23 duplication. These findings provide further support that 22q11.2 duplication predisposes to BEEC.
| MATERIALS AND METHODS

| Patients
Ninety two individuals with BEEC of white British descent were studied. They were recruited from a single center. All 92 had isolated BEEC of which 56 had CBE (37 male, 19 female), 18 had CE (7 male, 11 female), and 18 had epispadias (13 male, 5 female). Following ethical approval (HRA 68248) written informed consent was taken from all participants or their parent(s) if they were too young to provide consent. Blood or saliva was collected from index cases, and from their parents were possible, and genomic DNA was isolated using standard automated processes. A total of 12,500 unrelated individuals with developmental delay undergoing microarray analysis from our in house database were used as a comparator.
| SNP6 copy-number array analysis
DNA from index cases was analyzed for copy number variations using the Genome-Wide Human SNP Array 6.0 (Affymetrix, Inc., Santa Clara, CA). Genomic DNA was hybridized to a SNP6 array according to the manufacturer's instructions. Arrays were stained using a Fluidics Station 450 (Affymetrix, Inc.) and scanned using the GeneChip scanner 3000 7G system (Affymetrix, Inc.). Copy number data were generated using the SNP 6.0 CN/LOH Algorithm within the Affymetrix Genotyping console v4.2 and analyzed using Chromosome Analysis suite v2.1. The copy-number detection threshold was set to 0.02, with a minimum size of deletion/duplication of 100 kb. Chromosomal annotation is based on from NCBI Build 37/hg19.
| Droplet digital PCR
Droplet digital PCR (ddPCR) was carried out using the QX100 Droplet Digital PCR system (Bio-Rad Laboratories, Hemel Hempstead, UK). Forty cycles of PCR were performed using a Verity Thermal Cycler Droplets were analyzed using a Bio-Rad QX200 Droplet Digital Reader and CNV status was calculated with QuantaSoft software by comparing the ratio of fluorescent probes for the reference region and the region of interest.
| Sanger sequencing of CRKL
Primers were designed for individual exons of CRKL (NM_005207)_ with Primer3 (http://frodo.wi.mit.edu/). PCR was performed on genomic DNA and products purified using Agencourt AMPure XP (Beckman Coulter Genomics, Krefeld, Germany). DNA sequencing was performed using the BigDye Terminator Cycle Sequencing Kit (version 3.1; Life Technologies, Paisley, United Kingdom). Sequencing products were purified using Agencourt CleanSEQ (Beckman Coulter Genomics), and sequence analysis was performed using the ABI 3730xl DNA Analyzer (Life Technologies). Primer sequences and experimental conditions available on request.
| RESULTS
Six CNVs were identified comprising two duplications of 22q11.21, one distal duplication of 22q11.23, and three rare CNVs (Table 2) .
Screening of the microarray data from the 12,500 individuals in the in-house comparator group, predominantly undergoing testing for developmental delay, revealed 34 duplications at the 22q11.2 locus.
The overall incidence of 22q11.2 duplications in our total BEEC cohort of 92 patients compared with the total number of 12,500 controls was 3.3% (cohort) versus 0.27% (controls) (odds ratio 12.36; 95% confidence interval, 3.73-40.98; p < .0001). Here, and in Tables 1 and   2 , we provide details of individual patients and their genetic results. He has normal renal tract and his latest creatinine is 18 μM. The duplication was inherited from a healthy unaffected father.
The 22q11.21 and 22q11.23 duplications were orthogonally confirmed using ddPCR.
In addition, three CNVs of uncertain significance were identified in three unrelated individuals, as follows.
4. In a female with CE, a 1.4 Mb duplication was detected at 3p26.3 (955,800-2,101,328). This duplication encompasses CNTN6, coding for contactin 6. This patient's latest creatinine was 22 μM. 5. A male with CBE was found to carry a 3.3 Mb deletion on chromosome 4p15.2 (27, 110, 421, 576) n/a n/a = parents samples not available. Edelmann et al., 1999; Shaikh et al., 2007) . The most common rearrangements involving eight LCRs (LCR22A-LCR22H) (Edelmann et al., 1999) : 22q11.21 (18,884,837-21,611,337) ; (b) in a male proband with epispadias: 22q11.21 (19, 059, 465, 835) ; (c) in a male proband with CBE: 22q11.23 (23, 664, 064, 964) . Tracks were arranged from top to bottom showing copy number states (segments), Log2 ratio, and smooth signal [Color figure can be viewed at wileyonlinelibrary.com] 2 (BCRP2). (Draaken et al., 2014 (Wentzel, Fernström, Ohrner, Annerén, & Thuresson, 2008) . Human studies and mouse models suggest that sensitivity to gene dosage changes during embryogenesis and the existence of modifying factors determine the specific phenotype. Further work will be required to define these complex temporospatial relationships during normal and altered development.
For the three other larger CNVs that were identified in this cohort there is no prior evidence of these being associated with disorders of the lower urinary tract. The 3p26.3 duplication is in a region where microduplication has been associated with neurodevelopmental disorders (Hu et al., 2015) . Deletions at 4p15.2 have been observed in the Database of Genomic Variants (Coe et al., 2014; Cooper et al., 2011; Mills et al., 2011; Redon et al., 2006) without an associated phenotype. Larger duplications overlapping the 22q13.31 locus have been reported associated with neurodevelopmental disorders (Peeters, Vermeesch, & Fryns, 2008 ).
In conclusion, we provide further evidence that microduplications at 22q11.2 may manifest with nonsyndromic CBE and increase the likelihood that altered expression of a gene or genes within, or near to, this locus are key to the pathogenesis of this devastating congenital disorder.
